How it works
Binds pituitary GHRH receptors to increase both the amplitude of GH pulses and total GH secretion. The DAC (drug affinity complex) version binds serum albumin, extending the half-life from minutes to about a week.
Structure: 30 amino acid GHRH analogue
Reported benefits
- Elevated GH and IGF-1 across the dosing window
- Improved sleep depth reported by most users
- Supports lean mass retention and fat oxidation
Practical considerations
- Usually paired with a GHRP such as Ipamorelin for a synergistic pulse
- No-DAC (Mod GRF 1-29) suits pulsatile dosing; DAC suits steady elevation
- GH elevation is not desirable for everyone — screen for cancer history
Side effects and risks
- Water retention
- Tingling or numbness in hands
- Head rush and flushing after injection
- Elevated fasting glucose at higher doses
CJC-1295 dosing overview
100 mcg (no-DAC) 1–3× daily, or 1–2 mg weekly for the DAC version
| Context | Amount | Frequency | Route |
|---|---|---|---|
| CJC-1295 without DAC (mod GRF 1-29) | 100 mcg | 1–3× daily | Subcutaneous |
| CJC-1295 with DAC | 1–2 mg | Weekly | Subcutaneous |
This describes doses reported in published literature and community protocols. It is not a recommendation, and it is not a substitute for clinical supervision.
CJC-1295 FAQ
What does CJC-1295 do?
It is a GHRH analogue: it binds the growth-hormone-releasing-hormone receptor in the pituitary and raises the amount of growth hormone released, lifting the baseline rather than creating a single spike.
What is the difference between CJC-1295 with and without DAC?
The DAC version carries a drug-affinity complex that binds albumin, stretching half-life from roughly 30 minutes to 6–8 days. No-DAC dosing is frequent and pulse-like; DAC dosing is weekly and produces a sustained elevation.
Why is CJC-1295 paired with ipamorelin?
They act on two different receptors — GHRH and ghrelin. The pairing is described as complementary because one raises the amount available to release and the other triggers the pulse.
Is CJC-1295 approved?
No. Human development stopped after early trials; it is not FDA-approved, is restricted for US compounding, and is prohibited in sport.
Research references
- Teichman et al., 2006 — CJC-1295 pharmacokinetics in healthy adults